Ad
related to: spravato treatment center locator
Search results
Results from the WOW.Com Content Network
Ketamine-assisted psychotherapy (KAP) is the use of prescribed doses of ketamine, the drug, as an adjunct to psychotherapy sessions. KAP shows significant potential in treating mental disorders such as treatment-resistant depression (TRD), anxiety, obsessive–compulsive disorders (OCD), post-traumatic stress disorders (PTSD), and other conditions. [1]
Esketamine, sold under the brand names Spravato (for depression) and Ketanest (for anesthesia) among others, [ 10][ 12] is the S (+) enantiomer of ketamine. [ 5][ 13] It is a dissociative hallucinogen drug used as a general anesthetic and as an antidepressant for treatment of depression. Esketamine is the active enantiomer of ketamine in terms ...
Ketamine is a dissociative anesthetic used medically for induction and maintenance of anesthesia.It is also used as a treatment for depression and pain management. [19] It is a compound that was derived from phencyclidine in 1962 in pursuit of a safer anesthetic with fewer hallucinogenic effects.
Celebrities like Matthew Perry, Chrissy Teigen and others have been open about using ketamine infusion therapy to help treat mental health conditions. According to the United States Drug ...
A slightly different version of ketamine, called esketamine or Spravato, was approved by the FDA in 2019 for treatment-resistant depression. Esketamine is given as a nasal spray and must be ...
Hough spearheaded the development of J&J's nasal spray, Spravato, used to treat depression in combination with an oral drug. ... or MDMA-based PTSD treatment, citing limited data.
Reid Robison (born September 1976 in Illinois) is an American board-certified psychiatrist known primarily for his work with psychedelic medicines.As an early adopter and researcher of the use of ketamine in psychiatry, Robison has made significant contributions to ketamine-assisted psychotherapy (KAP) and other treatment modalities using ketamine for mental health conditions.
Lykos Therapeutics is cutting 75% of staff after FDA rejected its MDMA drug for mental health. The FDA's decision marks the first time the agency considered a psychedelic for medical use.
Ad
related to: spravato treatment center locator